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Abstract
Infection due to Streptococcus pneumoniae (SP) requiring hospitalization is common. However, recent clinical studies describing
patient characteristics and outcomes for SP infection in adults requiring hospitalization are lacking. Our goal was to evaluate patient
characteristics, contemporary antibiotic resistance, and clinical outcomes among hospitalized adults with SP infections.
A retrospective cohort study was conducted at Barnes-Jewish Hospital (1350 beds) in St. Louis, Missouri, USA for years 2012
through 2016. During the study period, 358 hospitalized adults, excluding those with meningitis, were identified with SP infection.
Forty-four patients (12.3%) died within 30 days of the identification of their infection. Among these infections, 99 (27.7%) were
assessed to be hospital-acquired and 259 (72.3%) were community-onset infections. The majority of infections involved the
respiratory tract (88.5%). Azithromycin resistance was the most common antibiotic resistance at 51.4%, followed by enteral penicillin
resistance (45.3%), trimethoprim-sulfamethoxazole (34.1%), second-generation cephalosporin (cefuroxime) (30.7%), and
meropenem (22.6%). There were 70 isolates (19.6%) classified as multidrug resistant. Independent predictors of hospital mortality
included increasing weight in 1-kilogram increments (adjusted odds ratio [AOR], 1.02; 95% CI, 1.01 – 1.02; P= .048), increasing
Charlson Comorbidity Index scores (AOR, 1.31; 95% CI, 1.21 – 1.42; P= .001), and the presence of septic shock (AOR, 3.89; 95%
CI, 2.31 – 6.57; P= .009). The median [interquartile range] hospital length of stay was 8.1 days [4.5 days, 16.8 days].
Hospitalized patients with infection attributed to SP have significant 30-day mortality and use of hospital resources. Antibiotic
resistance is common among isolates associated with infection. Determinants of mortality are primarily severity of illness, underlying
comorbidities and increasing patient weight. Efforts to improve the treatment and prevention of SP infections are needed.
Abbreviations: AOR = adjusted odds ratio, SP = Streptococcus pneumoniae.
Keywords: antibiotic resistance, clinical outcomes, septic shock, streptococcus pneumoniae
1. Introduction
Streptococcus pneumoniae (SP) is a common cause of commu-
nity-onset infection.[1] The ability of SP to readily colonize the
mucosal surfaces of the upper airways and evade host
inflammatory and immune responses contributes to its
transmission and virulence.[2] Pneumococcal diseases range
from mild respiratory tract mucosal infections such as otitis
media and sinusitis to diseases of greater severity including
meningitis, pneumonia and septic shock.[3] The Centers for
Disease Control and Prevention and other sources report
that there are up to 60,000 cases of invasive pneumococcal
infection each year, with at least 40% of the clinical isolates
being resistant to at least 1 antibiotic commonly employed for
empiric treatment of SP infections.[4,5] However, up to 30% of
SP isolates may be resistant to more than 1 antimicrobial
agent.[5,6]
Macrolide antibiotics are still employed as a treatment option
for infections attributed to SP depending on the prevailing
resistance rates.[7,8] Yet, rates of resistance to macrolides are
reported to be between 20%and 40%.[9,10] Several recent reports
suggest that macrolide resistance is much higher in specific
regions of the world with China recording greater than 90%
resistance in some areas.[11,12] The high rates of resistance to
macrolides are in large part related to the escalating global
consumption of macrolide antibiotics.[13–15] Given the rising
rates of macrolide resistance, and resistance of pneumococci to
other antibiotic classes, new antibiotics have been developed for
the treatment of antibiotic resistant SP infections.[16,17]
Due to the importance of SP as a cause of invasive infection, we
carried out a retrospective study with 2 main goals:
(1) to determine the contemporary rates of SP resistance to
antibiotics commonly employed to treat SP infections; and
(2) to assess the outcomes of infection with SP among
hospitalized adults.
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Given the aging and escalating rates of immune suppression
among both ambulatory individuals and hospitalized patients,
the numbers and severity of SP infections is expected to grow in
the future.[18]
2. Methods
2.1. Study population and data source
The study was conducted within Barnes-Jewish Hospital, an
academic referral center of 1350 beds. Washington University
School of Medicine Human Studies Committee (Institutional
Review Board # 201801189) and the St. Louis College of
Pharmacy (Institutional Review Board #2018–30) approved this
studyandwaived the need for informed consent.All patientswith a
microbiologically confirmed SP infection treated with antibiotics
fromJanuary 1, 2012 throughDecember 31, 2016were eligible for
inclusion with the exception of patients with meningitis. SP
meningitis was excluded due to the limited numbers typically seen
at our institution and the difference in disease severity compared to
other forms of SP infection. All data was derived from the
informatics database provided by the Center for Clinical
Excellence, BJC HealthCare, St. Louis, Missouri.
2.2. Study outcomes/objectives
The primary objective of this study was to determine the
contemporary rates of SP resistance to antibiotics commonly
employed to treat infections attributed to Gram-positive cocci.
The secondary objective of this study was to assess the outcomes
of infection with SP among hospitalized adults including 30-day
mortality and hospital length of stay.
2.3. Definitions and study design
SP infection was defined by themicrobiologic isolation of SP from
sterile sites (blood, pleural fluid, synovial fluid, ascites, bone) or
from skin and soft tissue sites or respiratory specimens in the
context of clinical features suggesting the presence of active
infection. For skin and soft tissue infections medical record
documentation of the presence of purulence or cellulitis was
required. For respiratory infections clinical criteria in line with
the American Thoracic Society position statement on pneumonia
were required.[19] These diagnostic criteria included presence of a
new or progressive radiographic infiltrate and at least 2 of the
following clinical features: fever >38°C, leukocytosis (>10
109cells/L), leukopenia (4109cells/L), or purulent respiratory
secretions. The presence of a new or progressive radiographic
infiltrate was based on the interpretation of the chest radiograph
by board-certified radiologists.
Septic shockwas defined as the need for vasopressors (norepineph-
rine, dopamine, vasopressin, epinephrine, orphenylephrine).Only the
first episode of documented SP infectionwas recorded. Antimicrobial
treatment was classified as initially appropriate antibiotic therapy if
the initial regimen had in vitro activity demonstrated against the SP
isolate. Multidrug-resistant isolates had to demonstrate in vitro
resistance to at least 3 distinct classes of antimicrobials that would
normally have activity against SP.[20]
2.4. Antimicrobial susceptibility testing
The microbiology laboratory performed antimicrobial suscepti-
bility testing of the bacterial isolates using the MICroSTREP Plus
minimum inhibitory concentration panel (Beckman Coulter,
Brea, California), with breakpoints established by the Clinical
Laboratory and Standards Institute published during the
inclusive years of the study.[21] For example, the breakpoint
for resistance to penicillin is greater than 2mg/L.[21] All
classifications of antibiotic resistance were based on in vitro
susceptibility testing using these established breakpoints.
2.5. Statistical analyses
The sample size was determined by a convenience sample of all
patients with SP infection identified in the hospital during the
study period. Continuous variables were expressed as mean and
standard deviation or median and interquartile range when
appropriate. The t test was used to analyze normally distributed
continuous variables, whereas the Mann–Whitney U test was
used to analyze non-normally distributed continuous variables.
Categorical data were reported as frequency distributions and
analyzed using the chi-square or Fisher exact tests. P values less
than .05 were considered statistically significant, and all tests
were 2-tailed. We performed multivariate logistic regression
analysis to identify risk factors associated with 30-day mortality.
All risk factors that were significant at the 0.20 level in the
univariate analyses were included in the corresponding multivar-
iable analysis. All variables entered into themodel were examined
for colinearity using the variance inflation factor as a colinearity
statistic. The model’s goodness of fit was assessed via
determination of the Hosmer-Lemeshow c-statistic. A sensitivity
analysis was also planned for the pneumonia subpopulation. All
analyses were done using SPSS Statistics 24 (IBM SPSS Statistics,
Version 24.0. Armonk, NY).
3. Results
During the study period, 358 patients excluding those with
meningitis were identifiedwithmonobacterial SP infection during
their hospitalization. Azithromycin resistance was the most
common antibiotic resistance observed at 51.4%, followed by
enteral penicillin resistance (45.3%), trimethoprim-sulfamethox-
azole (34.1%), second-generation cephalosporin (cefuroxime)
(30.7%), and meropenem (22.6%) (Table 1). There were 70
isolates (19.6%) classified as multidrug resistant. Thirty-day
nonsurvivors had greater resistance to second generation
cephalosporins, meropenem, and penicillin compared to 30-
day survivors (Table 1). Multidrug resistance and resistance to
second- and third-generation cephalosporins, meropenem,
amoxicillin-clavulanate, macrolides, tetracycline, clindamycin,
and trimethoprim sulfamethoxazole was statistically more
common among the non-bacteremic isolates. Hospital-acquired
isolates were statistically more likely to be resistant to second-
generation cephalosporins and clindamycin compared to com-
munity-acquired solates.
The mean age of patients was 55.6±15.1 years and the median
[interquartile range] for acute physiology and chronic health
evaluation II scores was 11 [7.0,15.3] (Table 2). SP infection was
more common among males (60.1%). Underlying chronic
obstructive pulmonary disease existed in 42.7% and active
malignancy was present in 29.6% of patients. The most common
infection was pneumonia (88.5%) (Table 3). Positive blood
cultures for SP were present in 33.2% of patients and forty-four
patients (12.3%) died within 30 days of the identification of their
infection (Tables 3 and 4). Among these infections, 99 (27.7%)
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were assessed to be hospital-acquired with 259 (72.3%) being
community-onset infections (Table 4). The median [interquartile
range] hospital length of stay was 8.1 days [4.5 days, 16.8 days].
Thirty-day nonsurvivors were significantly older, more likely
to be male, had greater weight, Charlson Comorbidity Index
scores, coronary artery disease, congestive heart failure, chronic
kidney disease and greater Acute Physiology and Chronic Health
Evaluation II scores compared to 30-day survivors (Table 2).
Sputum cultures were statistically more common for identifying
SP among 30-day survivors while tracheal aspirate cultures were
statistically more common for identifying SP among 30-day
nonsurvivors (Table 3). Thirty-day nonsurvivors more frequently
required mechanical ventilation, the use of vasopressors,
admission to the ICU setting, and were significantly more likely
to have a hospital-acquired infection (Table 4). Hospital duration
was similar between 30-day nonsurvivors and 30-day survivors.
The average patient weight of our study population was 80.6±
24.4kg. Figure 1 shows that survival post SP infection was
negatively associated with increasing weight. Patients within the
lowest weight tertile had the greatest survival while those within
the greatest weight tertile had the lowest survival from SP
infection. Logistic regression analysis identified independent
predictors of 30-day mortality as increasing weight in 1-kilogram
increments (adjusted odds ratio [AOR], 1.02; 95% CI, 1.01 –
1.02; P= .048), increasing Charlson Comorbidity Index scores
(AOR, 1.31; 95% CI, 1.21 – 1.42; P= .001), and the presence of
septic shock (AOR, 3.89; 95% CI, 2.31 – 6.57; P= .009)
(Hosmer-Lemeshow test, P= .473) (Table 5). Repeating the
logistic regression analysis for the 317 (88.5%) patient with
pneumonia yielded similar independent predictors for 30-day
mortality: increasing weight in 1-kilogram increments (AOR,
1.02; 95% CI, 1.01 – 1.02; P= .014), increasing Charlson
Table 1
Antibiotic resistance of the isolates.
Antibiotic Entire Cohort (n=358) 30-d nonsurvivors (n=44) 30-d survivors (n=314) P Value
Cefuroxime, n (%) 110 (30.7) 21 (47.7) 89 (28.3) .009
Ceftriaxone, n (%) 10 (2.8) 3 (6.8) 7 (2.2) .112
Cefepime, n (%) 22 (6.1) 5 (11.4) 17 (5.4) .124
Meropenem, n (%) 81 (22.6) 18 (40.9) 63 (20.1) .002
Vancomycin, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Amoxicillin clavulanate, n (%) 41 (11.5) 7 (15.9) 34 (10.8) .322
Azithromycin, n (%) 184 (51.4) 26 (59.1) 158 (50.3) .276
Tetracycline, n (%) 72 (20.1) 11 (25.0) 61 (19.4) .388
Clindamycin, n (%) 54 (15.1) 10 (22.7) 44 (14.0) .130
Trimethoprim sulfamethoxazole, n (%) 122 (34.1) 20 (45.5) 102 (32.5) .089
Levofloxacin, n (%) 7 (2.0) 1 (2.3) 6 (1.9) 1.000
Chloramphenicol, n (%) 7 (2.0) 1 (2.3) 6 (1.9) 1.000
Penicillin (intravenous), n (%) 27 (7.5) 7 (15.9) 20 (6.4) .025
Penicillin (enteral), n (%) 162 (45.3) 27 (61.4) 135 (43.0) .025
Multidrug resistant,
∗
n (%) 70 (19.6) 12 (27.3) 58 (18.5) 1.168
Values expressed as number (percent).
∗
Resistant to at least 3 antibiotic classes commonly employed for the treatment of Streptococcus pneumoniae infections.
The P values are for the comparison between 30-d nonsurvivors and survivors.
Table 2
Baseline characteristics.
Characteristic Entire Cohort (n=358) 30-d nonsurvivors (n=44) 30-d survivors (n=314) P value
Age, yr 55.6±15.1 61.0±15.2 54.8±15.0 .011
Male, n (%) 215 (60.1) 34 (77.3) 181 (57.6) .013
African American, n (%) 121 (33.4) 14 (31.8) 107 (34.1) .767
Caucasian, n (%) 217 (60.6) 28 (63.6) 189 (60.2) .661
Other race, n (%) 20 ((5.6) 2 (4.5) 18 (5.7) 1.000
Weight, kg 80.6±24.4 91.3±32.4 79.1±22.7 .002
Charlson Comorbidity Score 4 [2.0,7.0] 7 [3.3,9.1] 4 [2.0,6.0] <.001
Coronary artery disease, n (%) 51 (14.2) 12 (27.3) 39 (12.4) .008
Congestive heart failure, n (%) 80 (22.3) 16 (36.4) 64 (20.4) .017
Chronic obstructive pulmonary disease, n (%) 153 (42.7) 22 (50.0) 131 (41.7) .298
Cirrhosis, n (%) 52 (14.5) 7 (15.9) 45 (14.3) .781
Diabetes mellitus, n (%) 83 (23.2) 10 (22.7) 73 (23.2) .939
Chronic kidney disease, n (%) 61 (17.0) 13 (29.5) 48 (15.3) .018
Underlying malignancy, n (%) 106 (29.6) 15 (34.1) 91 (29.0) .487
Human immunodeficiency virus, n (%) 10 (2.8) 1 (2.3) 9 (2.9) 1.000
Hospitalized in previous 90 days, n (%) 95 (26.5) 15 (34.1) 80 (25.5) .226
APACHE II Score 11 [7.0,15.3] 13 [9.0,18.8] 11 [7.0,15.0] .003
Values expressed as number (percent), median with 25th and 75th percentile, mean plus/minus standard deviation. APACHE= acute physiology and chronic health evaluation. The P values are for the comparison
between 30-d nonsurvivors and survivors.
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Comorbidity Index scores (AOR, 1.25; 95% CI, 1.18 – 1.32;
P< .001), and the presence of septic shock (AOR, 4.41; 95% CI,
3.09 – 6.32; P< .001) (Hosmer-Lemeshow test, P= .996).
4. Discussion
We found that more than 50% of the SP clinical isolates
associated with infection among hospitalized adults were
resistant to azithromycin. Moreover, almost 20% of all SP
isolates were classified as multidrug resistant. Overall thirty-day
mortality was 12.3% and greater than a quarter of the infections
were hospital acquired. Independent risk factors for 30-day
mortality included increasing weight, greater comorbidities as
assessed by the Charlson Comorbidity Index score and the
presence of septic shock requiring vasopressor administration.
Initially appropriate antibiotic therapy was delivered in more
than 90%of patients despite the high rate of antibiotic resistance.
This was likely due to the antibiotic treatment protocols at
Barnes-Jewish Hospital recommending inpatient treatment with
a third generation cephalosporin antibiotic or broader, often in
combination with other agents, for patients with serious
infections admitted from the community setting or developing
hospital-acquired infections as outlined in the Barnes-Jewish
Hospital Tool Book.[22]
Antibiotic resistance among SP isolates has been increasing
steadily in the United States as reported by several groups
including the Center for Disease Control and Prevention.[4,9,10,23]
Unfortunately, most invasive pneumococcal disease primarily
affects young children, adults over the age of 65 years, and
individuals with underlying immune suppression and significant
Table 3
Positive microbiologic cultures and infection site.
Culture and infection site Entire Cohort (n=358) 30-d nonsurvivors (n=44) 30-d survivors (n=314) P value
Culture Site
Bronchoalveolar lavage, n (%) 40 (11.2) 8 (18.2) 32 (10.2) .115
Sputum, n (%) 50 (14.0) 1 (2.3) 49 (15.6) .018
Tracheal aspirate, n (%) 121 (33.8) 25 (56.8) 96 (30.6) .001
Blood culture, n (%) 119 (33.2) 10 (22.7) 109 (34.7) .114
Abdominal fluid, n (%) 2 (0.6) 1 (2.3) 1 (0.3) .866
Soft tissue abscess, n (%) 8 (2.2) 0 (0.0) 8 (2.5) .603
Soft tissue aspirate, n (%) 2 (0.6) 0 (0.0) 2 (0.6) 1.000
Bile, n (%) 2 (0.6) 0 (0.0) 2 (0.6) 1.000
Bone, n (%) 2 (0.6) 0 (0.0) 2 (0.6) 1.000
Cutaneous cyst, n (%) 1 (0.3) 0 (0.0) 1 (0.3) 1.000
Cellulitis associated skin drainage, n (%) 2 (0.6) 0 (0.0) 2 (0.6) 1.000
Ocular swab, n (%) 1 (0.3) 0 (0.0) 1 (0.3) 1.000
Pleural fluid, n (%) 7 (2.0) 1 (2.3) 6 (1.9) 1.000
Synovial fluid, n (%) 2 (0.6) 0 (0.0) 2 (0.6) 1.000
Deep myocutaneous culture, n (%) 3 (0.8) 0 (0.0) 3 (1.0) 1.000
Cutaneous ulcer, n (%) 1 (0.3) 0 (0.0) 1 (0.3) 1.000
Wound, n (%) 10 (2.8) 0 (0.0) 10 (3.2) .618
Multiple positive culture sites, n (%) 15 (4.2) 2 (4.5) 13 (4.1) 1.000
Total positive respiratory specimens, n(%) 218 (60.9) 35 (79.5) 183 (58.3) .007
Total positive soft tissue specimens, n(%) 27 (7.5) 0 (0.0) 27 (8.6) .043
Infection Site
Pneumonia 317 (88.5) 41 (93.2) 276 (87.9) .972
Intra-abdominal infection 4 (1.1) 1 (2.3) 3 (1.0) .940
Other
∗
37 (10.3) 2 (4.5) 35 (11.1) .898
Values expressed as number (percent). The P values are for the comparison between 30-day nonsurvivors and survivors.
∗
Other includes skin and soft tissue infection sites (n=34), bone (n=2), and ocular (n=1).
Table 4
Process of care variables and outcomes.
Variable and outcome Entire Cohort (n=358) 30-d nonsurvivors (n=44) 30-d survivors (n=314) P value
Mechanical ventilation, n (%) 171 (47.8) 32 (72.7) 139 (44.3) <.001
Vasopressors, n (%) 117 (32.7) 29 (65.9) 88 (28.0) <.001
Corticosteroids, n (%) 137 (38.3) 17 (38.6) 120 (38.2) .957
Intensive care unit admission, n (%) 215 (60.1) 37 (84.1) 178 (56.7) .001
Combination antibiotic treatment, n (%) 239 (66.8) 27 (61.4) 212 (67.5) .417
Appropriate initial treatment, n (%) 327 (91.3) 40 (90.9) 287 (91.4) .913
Hours to appropriate treatment 3 [1.0,12.0] 1 [1.0,9.0] 3 [1.0,12.0] .369
Hospital day positive culture 1 [1.0,3.0] 1.5 [1.0,5.0] 1 [1.0,3.0] .022
Hospital acquired infection, n (%) 99 (27.7) 18 (40.9) 81 (25.8) .036
In hospital mortality, n (%) 38 (10.6) 37 (84.1) 1 (0.3) <.001
Hospital d 8.1 [4.5,16.8] 7.4 [4.7,15.9] 8.3 [4.4,16.8] .906
Values expressed as number (percent) and median with 25th and 75th percentile. The P values are for the comparison between 30-d nonsurvivors and survivors.
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comorbidities.[24] Our study demonstrated high rates of
antibiotic resistance among hospitalized adults with pneumococ-
cal infections. This finding is in line with the report by Keedy and
associates presented at the 2016 ID Week meeting showing that
33% of all SP isolates demonstrated high level resistance to
macrolides.[25] An important aspect of our study, compared to
other investigations that have focused on the outpatient setting
where oral agents such as macrolides are commonly employed, is
that we exclusively evaluated a hospitalized population.[26,27]
However, it is worth noting that in some cases, lack of outpatient
treatment with an appropriate agent active against the SP isolate
has led to life-threatening disease including the need for
extracorporeal membrane oxygenation.[28]
A unique finding of our study was the association between
increasing patient weight and 30-day mortality. Several studies in
children or adults suggest that both underweight and obesity are
associated with increased infection risk.[29] However, confound-
ing factors such as malnutrition, hygienic status and underlying
disease or co-morbidities might aggravate accurate assessment of
the impact of body weight on infection risk. Obesity specifically is
thought to primarily increase overall mortality by escalating
certain disease processes such as diabetes mellitus, coronary
artery disease, cancer, and renal disease.[30]
Obesity is also thought to negatively influence immune
function and host defense mechanisms. One potential pathway
for this influence is that obesity is an inflammatory condition
associated with chronic activation of the immune system and
consequent local and systemic inflammation.[31] This state of
chronic inflammation, associated with other influences of obesity
such as diabetes, can negatively impact the immune system by
reducing immune responses resulting in an increased risk of
infection.[31] Moreover, obesity can induce a state of meta-
flammation in which excess nutrients, due to inefficient glucose
metabolism, promote chronic low-grade inflammation the
hallmarks of which are high levels of glucose, lipids, free fatty
acids, and reactive oxygen species.[32] Frasca et al also recently
suggested that obesity could increase the prevalence of
pneumococcal disease, and potentially worsen the outcome of
infected patients, due to the combined effects of increased
comorbidities such as diabetes in conjunction with the reduced
immune response promoted by chronic inflammation.[33]
There are several important limitations of our study. First, these
datawereobtained froma singleurbanmedical center. It is possible
that our findings may differ from those obtained at other centers
due to differences in patient casemix and disease severity. The high
rate of hospital-acquired SP infections in our cohort is likely a
reflection of the overall disease mix of our patient population as
previously demonstrated.[34] Second, we employed patient weight
and not the body mass index due to the lack of patient height data
in the electronic medical record. This may have influenced our
finding of a relationship between weight and 30-day mortality.
However, other studies have demonstrated that body mass index
may not be an accurate method for determining the presence of
obesity suggesting that body weight is an appropriate marker for
study purposes.[35,36] Third, we did not collect outpatient data
including prior antibiotic therapy. This may be an important
contributor to patient outcomes that our study way not able to
account for. Fourth, the sample size of our study population may
have limited our ability to identify all of the important risk factors
for 30-day mortality. Finally, we did not assess the individual SP
isolates to determine whether specific virulence factors may have
contributed to the observed patient outcomes.[37]
In conclusion, our study demonstrates that hospitalized
patients with SP infection have significant 30-day mortality
and use of hospital resources. Antibiotic resistance, especially to
macrolides and second-generation cephalosporins, is common
among SP isolates associated with infection. Determinants of
mortality for SP infections are primarily severity of illness,
comorbidities and increasing patient weight. Efforts aimed at
improving the treatment and prevention of infections caused by
SP are required. Such efforts may include targeted vaccination
programs for patients at high risk for developing SP infection
including patients with obesity and the use of macrolide
antibiotics as adjunctive treatment when a high systemic
inflammatory response is present .[38,39] The latter has been
the rationale for including macrolides as part of the treatment
regimen for SP infections even when resistance is demonstrat-
ed.[40] Additional investigations are warranted to verify our
findings and to determine the optimal treatment approaches for
SP infections. Developing new prevention strategies and
treatment paradigms for SP infections is critical given the lack
of mortality improvement with this infection over the past twenty
years.[41]
Figure 1. Kaplan-Meier survival curves depicting the tertiles of body weight
among patients with Streptococcus pneumoniae infection. Tertile weight
range: lowest tertile, 34.1kg to 67.6kg; intermediate tertile, 68.0kg to 86.7kg;
highest tertile, 87.0kg to 206.9kg. The solid line shows the patients within the
lowest weight tertile. The dashed line represents the patients within the
intermediate weight tertile. The dotdashed line shows the patients within the
highest weight tertile. (Tarone-Ware statistic, P= .044.).
Table 5
Independent Predictors of Hospital Mortality.
Variable Adjusted odds ratio 95% CI P Value
Weight (1 kg increments) 1.02 1.01 – 1.02 .048
Charlson comorbidity index 1.31 1.21 – 1.42 .001
Shock requiring vasopressors 3.89 2.31 – 6.57 .009
Hosmer-Lemeshow test, P= .473.
CI = confidence interval.
Micek et al. Medicine (2020) 99:18 www.md-journal.com
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